TRex Bio, Inc., a biotechnology company focused on deciphering human tissue immune biology to create innovative therapeutics, has announced a significant milestone. Its partner, Eli Lilly and Company, has initiated a Phase 1 first-in-human study of TRB-051

Roche has received approval from the European Commission for OCREVUS® (ocrelizumab) subcutaneous (SC) formulation, expanding its use to treat both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis

Exsilio Therapeutics, a biotechnology company focused on developing genomic medicines for a wide range of diseases, has announced its emergence from stealth mode after securing $82 million in Series A financing

Silence Therapeutics plc, a leading biotechnology company specializing in precision-engineered medicines for treating diseases, has announced a significant milestone in its partnership with Hansoh Pharmaceutical Group Company Limited

4D Molecular Therapeutics has obtained FDA clearance for its Investigational New Drug Application for 4D-175, an intravitreal genetic medicine utilizing the R100 vector, intended for treating geographic atrophy

Bristol Myers Squibb announced today that the U.S. Food and Drug Administration has granted accelerated approval for KRAZATI® in combination with cetuximab as a targeted treatment for adult patients

Takeda announced today that the European Commission has approved FRUZAQLA as a monotherapy for the treatment of adults with metastatic colorectal cancer (mCRC) who have previously undergone standard therapies

Sanofi and Biovac, a South African biopharmaceutical company based in Cape Town, have announced a partnership to manufacture inactivated polio vaccines (IPV) locally in Africa. This collaboration

Kyverna Therapeutics, Inc. has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application concerning KYV-101, an autologous, fully human anti-CD19 chimeric antigen receptor

Sobi® has received approval from the European Commission for ALTUVOCT™, a replacement therapy designed for treating and preventing bleeds, as well as for perioperative prophylaxis in individuals with hemophilia